NASDAQ:OPRX OptimizeRx (OPRX) Stock Price, News & Analysis $4.99 +0.34 (+7.31%) (As of 11/26/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About OptimizeRx Stock (NASDAQ:OPRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get OptimizeRx alerts:Sign Up Key Stats Today's Range$4.50▼$5.0950-Day Range$3.83▼$8.1652-Week Range$3.78▼$16.65Volume510,413 shsAverage Volume151,991 shsMarket Capitalization$91.92 millionP/E RatioN/ADividend YieldN/APrice Target$10.42Consensus RatingModerate Buy Company OverviewOptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.Read More… The Great AI-Energy Collision (Ad)The biggest players in AI and tech are desperate to bring this limitless power source online. And fast. It’s the only way they can compete in their race for AI dominance. A handful of energy stocks are going to emerge from this transformation to dominate the sector. Get the full story here, while you still can. OptimizeRx Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks53rd Percentile Overall ScoreOPRX MarketRank™: OptimizeRx scored higher than 53% of companies evaluated by MarketBeat, and ranked 354th out of 643 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingOptimizeRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOptimizeRx has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about OptimizeRx's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for OptimizeRx are expected to grow in the coming year, from ($0.35) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptimizeRx is -3.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptimizeRx is -3.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOptimizeRx has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.02% of the float of OptimizeRx has been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in OptimizeRx has recently increased by 4.80%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOptimizeRx does not currently pay a dividend.Dividend GrowthOptimizeRx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.02% of the float of OptimizeRx has been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in OptimizeRx has recently increased by 4.80%, indicating that investor sentiment is decreasing. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 6 people have searched for OPRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added OptimizeRx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, OptimizeRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.10% of the stock of OptimizeRx is held by insiders.Percentage Held by Institutions76.47% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OptimizeRx's insider trading history. Receive OPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter. Email Address OPRX Stock News HeadlinesBrokerages Set OptimizeRx Co. (NASDAQ:OPRX) PT at $11.58November 19, 2024 | americanbankingnews.comOptimizeRx to Participate in Upcoming Investor ConferencesNovember 18, 2024 | globenewswire.comThe Great AI-Energy CollisionThe biggest players in AI and tech are desperate to bring this limitless power source online. And fast. It’s the only way they can compete in their race for AI dominance. A handful of energy stocks are going to emerge from this transformation to dominate the sector. November 26, 2024 | Porter & Company (Ad)OptimizeRx price target lowered to $8 from $13 at StifelNovember 15, 2024 | markets.businessinsider.comOptimizeRx price target lowered to $8 from $16 at JMP SecuritiesNovember 15, 2024 | markets.businessinsider.comOptimizeRx (OPRX) Gets a Buy from Stifel NicolausNovember 15, 2024 | markets.businessinsider.comOptimizeRx Reports Strong Revenue Growth in Q3 2024November 14, 2024 | markets.businessinsider.comOptimizeRx: Buy Rating Affirmed Amid Financial Efficiency and Business Model ShiftNovember 14, 2024 | markets.businessinsider.comSee More Headlines OPRX Stock Analysis - Frequently Asked Questions How have OPRX shares performed this year? OptimizeRx's stock was trading at $14.31 at the beginning of 2024. Since then, OPRX shares have decreased by 65.1% and is now trading at $4.99. View the best growth stocks for 2024 here. How were OptimizeRx's earnings last quarter? OptimizeRx Co. (NASDAQ:OPRX) issued its quarterly earnings data on Tuesday, May, 14th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.16. The company earned $19.69 million during the quarter, compared to analysts' expectations of $18.66 million. OptimizeRx had a negative net margin of 27.41% and a negative trailing twelve-month return on equity of 4.92%. Who are OptimizeRx's major shareholders? OptimizeRx's top institutional investors include Rice Hall James & Associates LLC (3.36%), Geode Capital Management LLC (2.16%), Essex Investment Management Co. LLC (1.32%) and Bullseye Asset Management LLC (1.17%). Insiders that own company stock include William J Febbo, James Paul Lang, Marion Odence-Ford, Stephen L Silvestro, Edward Stelmakh, Ellen O'connor Vos and Miriam J Paramore. View institutional ownership trends. How do I buy shares of OptimizeRx? Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of OptimizeRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that OptimizeRx investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC). Company Calendar Last Earnings5/14/2024Today11/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorComputer and Technology Industry Business services, not elsewhere classified Sub-IndustryBusiness Services Current SymbolNASDAQ:OPRX CUSIPN/A CIK1448431 Webwww.optimizerx.com Phone(248) 651-6568Fax248-453-5529Employees100Year FoundedN/APrice Target and Rating Average Stock Price Target$10.42 High Stock Price Target$18.50 Low Stock Price Target$5.00 Potential Upside/Downside+108.8%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,570,000.00 Net Margins-27.41% Pretax Margin-37.84% Return on Equity-4.92% Return on Assets-3.41% Debt Debt-to-Equity Ratio0.29 Current Ratio3.23 Quick Ratio3.23 Sales & Book Value Annual Sales$71.52 million Price / Sales1.29 Cash FlowN/A Price / Cash FlowN/A Book Value$6.97 per share Price / Book0.72Miscellaneous Outstanding Shares18,420,000Free Float17,297,000Market Cap$91.92 million OptionableOptionable Beta1.32 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:OPRX) was last updated on 11/26/2024 by MarketBeat.com Staff From Our PartnersA “Thank You Gift” From Pres. Trump - GeniusTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | Sponsored140% Yields From Stocks Like Tesla? Here's How (Black Friday Special)140% Dividends from stocks like Tesla? Discover How for Just $9! For Black Friday, get the full details of ...Investors Alley | Sponsored9 hidden AI stocks set to thrive in Trump’s new eraAI ETFs are Booming, But These 9 AI Stocks are Better Plays By 2030, the AI industry is projected to be wor...StockEarnings | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored❗[Investor Alert] Under-the-Radar TechWhile most investors are caught up in cryptocurrencies, AI stocks, or Jim Cramer's latest "hot pick…" One c...TuneGO | SponsoredThis Crisis Could Be Worse Than 2008Underneath the surface, cracks are forming. Cracks that threaten to shatter everything we know. America ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptimizeRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.